AnHeart Therapeutics Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Zhejiang, China (2018)

Organization Overview

First Clinical Trial
2020
NCT04395677
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

AnHeart Therapeutics Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

ab-106 (5 trials)

ds-1001b (2 trials)

Drugs in Phase 1 Trials (3)

digoxin (lanoxin) (1 trial)

itraconazole (sporanox) (1 trial)

rifampin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 5